TR200400227T4 - Skualen epoksidaz inhibitör ve makrolid immünmodülatör içeren farmasötik kompozisyon - Google Patents

Skualen epoksidaz inhibitör ve makrolid immünmodülatör içeren farmasötik kompozisyon

Info

Publication number
TR200400227T4
TR200400227T4 TR2004/00227T TR200400227T TR200400227T4 TR 200400227 T4 TR200400227 T4 TR 200400227T4 TR 2004/00227 T TR2004/00227 T TR 2004/00227T TR 200400227 T TR200400227 T TR 200400227T TR 200400227 T4 TR200400227 T4 TR 200400227T4
Authority
TR
Turkey
Prior art keywords
fungal
squalene epoxidase
pharmaceutical composition
composition containing
epoxidase inhibitor
Prior art date
Application number
TR2004/00227T
Other languages
English (en)
Inventor
Stewart Ryder Neil
Karl Mayer Friedrich
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of TR200400227T4 publication Critical patent/TR200400227T4/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Özellikle mantar ya da süpheli mantar enfeksiyonuna yer veren hastaliklarin tedavisi; atopik dermatit ve seboroeik dermatit gibi, örnegin ciltte meydana gelen mantar ya da süpheli mantar kolonizasyonunun rol oynadigi durumlarda immünmodülasyon ya da immünsupresyon; mantar direnci durumlari için, terbinafin gibi bir skualen epoksidaz inhibitör ve 33-epikloro, 33-desoksiaskomisin gibi bir makrolid T-hücre immünmodülatör ya da immünsupresana ait sinerjistik kombinasyonlar temin edilmistir.
TR2004/00227T 2000-02-18 2001-02-16 Skualen epoksidaz inhibitör ve makrolid immünmodülatör içeren farmasötik kompozisyon TR200400227T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0003932.1A GB0003932D0 (en) 2000-02-18 2000-02-18 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
TR200400227T4 true TR200400227T4 (tr) 2004-04-21

Family

ID=9886001

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2004/00227T TR200400227T4 (tr) 2000-02-18 2001-02-16 Skualen epoksidaz inhibitör ve makrolid immünmodülatör içeren farmasötik kompozisyon

Country Status (15)

Country Link
US (1) US6919317B2 (tr)
EP (1) EP1255564B1 (tr)
JP (1) JP3841682B2 (tr)
CN (1) CN100400103C (tr)
AT (1) ATE253939T1 (tr)
AU (1) AU2001254647A1 (tr)
BR (1) BR0108403A (tr)
CA (1) CA2399971C (tr)
DE (1) DE60101213T2 (tr)
DK (1) DK1255564T3 (tr)
ES (1) ES2210150T3 (tr)
GB (1) GB0003932D0 (tr)
PT (1) PT1255564E (tr)
TR (1) TR200400227T4 (tr)
WO (1) WO2001060345A2 (tr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
GB0125443D0 (en) 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
US7452692B2 (en) * 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
US8163726B2 (en) * 2002-09-18 2012-04-24 University Of Pennsylvania Method of inhibiting choroidal neovascularization
WO2004071510A1 (en) * 2003-02-11 2004-08-26 Cipla Ltd Pharmaceutical composition comprising immunosuppressants for the treatment of dermatophytosis
GB0307864D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307869D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
ES2389443T3 (es) * 2004-04-08 2012-10-26 Meda Pharma S.À.R.L. Composición de espuma de pimecrolimus que contiene hexilenglicol, opcionalmente alcohol de oleílo, dimetilisosorbida y/o triglicéridos de cadena media
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
JP4974903B2 (ja) 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物
WO2006103638A2 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Topical pharmaceutical compositions of terbinafine and processes for their preparation
GB0508827D0 (en) * 2005-04-29 2005-06-08 Novartis Ag Cosmeceutical composition
US20090082469A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched terbinafine
US20120277193A1 (en) * 2009-09-21 2012-11-01 President And Fellows Of Harvard College Synergistic Combination Therapy
EP3741367A1 (en) 2019-05-21 2020-11-25 Premark Pharma GmbH Treatment of ocular disease
WO2024209038A1 (en) 2023-04-06 2024-10-10 Premark Pharma Gmbh Use of pimecrolimus for the treatment of dry eye in patients characterized by a corneal staining score of 4 or 5 on the oxford grading scale

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3244592A (en) * 1962-06-09 1966-04-05 Arai Tadashi Ascomycin and process for its production
DK0427680T3 (da) 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
HU223343B1 (hu) * 1991-05-20 2004-06-28 Novartis Ag. Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
ATE299017T1 (de) * 1994-10-26 2005-07-15 Novartis Pharma Gmbh Arzneimittel
GB9509631D0 (en) * 1995-05-12 1995-07-05 Sandoz Ltd Antifungal combination
DE19544507B4 (de) * 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
AU9785698A (en) * 1997-10-02 1999-04-27 Microcide Pharmaceuticals, Inc. Fungal efflux pump inhibitors

Also Published As

Publication number Publication date
DE60101213T2 (de) 2004-08-19
CN1400909A (zh) 2003-03-05
AU2001254647A1 (en) 2001-08-27
EP1255564B1 (en) 2003-11-12
CA2399971A1 (en) 2001-08-23
US6919317B2 (en) 2005-07-19
CN100400103C (zh) 2008-07-09
ATE253939T1 (de) 2003-11-15
JP2003522783A (ja) 2003-07-29
DE60101213D1 (de) 2003-12-18
ES2210150T3 (es) 2004-07-01
WO2001060345A3 (en) 2002-04-18
EP1255564A2 (en) 2002-11-13
CA2399971C (en) 2009-10-06
BR0108403A (pt) 2003-03-11
WO2001060345A2 (en) 2001-08-23
PT1255564E (pt) 2004-03-31
HK1052633A1 (en) 2003-09-26
JP3841682B2 (ja) 2006-11-01
GB0003932D0 (en) 2000-04-12
US20030100517A1 (en) 2003-05-29
DK1255564T3 (da) 2004-02-09

Similar Documents

Publication Publication Date Title
TR200400227T4 (tr) Skualen epoksidaz inhibitör ve makrolid immünmodülatör içeren farmasötik kompozisyon
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
WO2006136420A3 (en) Methods and means for protecting the skin against pathogenic microorganisms
WO2008041966A3 (en) Broad spectrum antibacterial compounds
CL2012001080A1 (es) Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida.
BR9808520A (pt) Medicamento vaginal de lactobacilos
WO2002100455A3 (en) Use of ozone for the prevention of infection caused by medical devices
BR0116216A (pt) Inibidores de girase e seus usos
WO2005000878A3 (en) Compositions of lipopeptide antibiotic derivatives and methods of use thereof
BRPI9510423B8 (pt) formulação lipossomal multilamelar de baixa rigidez, e, formulação antiinfecciosa
CY1108165T1 (el) ΤΟΠΙΚΗ ΧΡΗΣΗ ΔΟΛΩΜΑΤΟΣ NF-κΒ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΤΗΣ ΑΤΟΠΙΚΗΣ ΔΕΡΜΑΤΙΤΙΔΑΣ
WO2005070940A3 (en) Rifamycin derivatives effective against drug-resistant microbes
Herruzo-Cabrera et al. Evaluation of the penetration strength, bactericidal efficacy and spectrum of action of several antimicrobial creams against isolated microorganisms in a burn centre
AU2003241345A1 (en) Use of mastic and its components for the control of microbial infections
BRPI0409187A (pt) composição farmacêutica contendo um imunossupressor para uso no tratamento de doenças de pele
PL402550A1 (pl) Dopochwowe kompozycje farmaceutyczne oraz zastosowanie zródla nadtlenku i bioadhezyjnego nosnika
ES2178761T3 (es) Utilizacion de 1-hidroxi-2-piridonas para el tratamiento de infe cciones cutaneas.
EP3305305A3 (en) Silicate containing compositions and methods of treatment
WO2003009859A1 (en) Immunotherapy for humans
TR200403001T3 (tr) Lovastatin ve simvastatinin, azaltılmış dimerik katışkı seviyelerine sahip olacak şekilde arıtılması için bir işlem
EP4344749A3 (en) Protease formulation for treatment of microbial infections
EP2250887A3 (en) Use of non-antibacterial tetracycline analog CMT-1002 and formulations thereof for the treatment of bacterial exotoxins
WO2006138571A3 (en) Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance
BR0309055A (pt) Uso combinado de l-carnitina, acetil l-carnitina e propionil l-carnitina para o tratamento da oligoastenoteratospermia
Sharma et al. Isolation and Characterization of Microflora from Bluetooth (ear buds) of young students at MIET, Meerut